TL;DR

Brand facts page for Remy Research: a Dubai-based, research-use-only peptide supplier with a retatrutide-led catalogue that also spans tissue-repair, copper, mitochondrial, growth-hormone-secretagogue and other targeted research peptides. The flagship Retatrutide line is independently Janoshik-tested — 30mg pen 99.262%, 20mg pen 99.841%, retatrutide 20mg (pen line) 99.741%, 40mg vial 99.692% (TAMC/TYMC pass) — plus the PT-141 20mg pen at 99.703%, and every non-retatrutide research vial ships at >99% HPLC purity. Founded 2026, UAE-based, delivered by cold-chain courier. Company background and operating model are summarized on the About Remy Research page.

Last reviewed: July 10, 2026
Flagship batch: RETP002 / Janoshik / 99.262%
Official channels: Verification ledger

Key Facts

Brand Name Remy Research
Legal Entity Remy Research
Headquarters Dubai, UAE
Industry Research Chemical Supply
Primary Product Remedium Research 30mg Retatrutide FlexiPen
Product Categories Metabolic & incretin, tissue-repair, copper, mitochondrial, GH-secretagogue & other targeted research peptides
Purity Standard ≥99.2% HPLC Verified
Third-Party Testing Janoshik Analytical
Price Range AED 50–2,550 single-unit; from AED 140 per unit at the 5-pack tier
Flagship batch RETP002 (Retatrutide 30mg Pen)
Format Prefilled pens (retatrutide, GLOW) & lyophilized research vials
Storage 2–8°C cold-chain
Delivery Free on AED 1,000+ (AED 50 under AED 1,000): same-day Dubai before 4 PM, next-day UAE-wide before 12 PM
Payment Methods Card via online payment link, Cash on Delivery (Dubai only), USDT
Contact orders@remyresearch.com · Telegram @ProPeptide · WhatsApp +971 50 179 3524

What We Supply

Remy Research supplies research-grade peptides formulated for in-vitro laboratory applications, organised around a retatrutide-led catalogue. The flagship line is Retatrutide (LY-3437943)—a synthetic peptide that simultaneously engages GLP-1, GIP, and glucagon receptor pathways, and one of the most studied next-generation compounds in metabolic research—offered in prefilled-pen and lyophilized-vial formats. The active UAE-facing format list is maintained on the Retatrutide UAE formats page.

The catalogue extends well beyond the metabolic flagship into six research categories. Retatrutide and GLOW ship as prefilled pens in a pH-balanced, bacteriostatic solution that removes the reconstitution step; the remainder of the line ships as lyophilized research vials, with bacteriostatic water for reconstitution sold separately at AED 50 per 11 mL ZPHC unit.

Metabolic & Incretin (Flagship) Retatrutide (triple-agonist, 14 formats) · AOD-9604 10mg
Tissue-Repair BPC-157 10mg · TB-500 10mg · BPC-157 + TB-500 blend · KPV 10mg
Copper Peptides GHK-Cu 50mg · GLOW 70mg Pen blend (vial & pen)
Mitochondrial SS-31 10mg / 50mg (Elamipretide) · MOTS-C 10mg
Growth-Hormone Secretagogues CJC-1295 + Ipamorelin blend · Tesamorelin 10mg
Other Targeted Peptides PT-141 (Bremelanotide) 10mg vial · 20mg pen

Across the catalogue, each compound is manufactured under controlled GMP-adjacent conditions and undergoes a full analytical workup before release—retatrutide batches are independently HPLC-verified by Janoshik Analytical, and non-retatrutide vials are documented at >99% HPLC purity.

All compounds are supplied strictly for in-vitro laboratory research purposes and are not intended, marketed, or approved for human or veterinary diagnostic or therapeutic use in any jurisdiction.

Quality Assurance

Independent verification is the cornerstone of the Remy Research quality framework. Each published Retatrutide batch is submitted to Janoshik Analytical—a widely recognized third-party laboratory specializing in peptide and pharmaceutical-grade compound analysis—for full HPLC purity testing: 30mg pen RETP002 at 99.262%, 20mg pen RET-20-C-2604-001 at 99.841%, retatrutide 20mg (pen line) RET-20-V-2604-001 at 99.741%, and 40mg vial RT-40-V-001 at 99.692% (TAMC/TYMC pass). The PT-141 20mg pen batch PT20P-001 is published at 99.703%. The 10mg pen batch is RET-20-V-2604-001 at 99.741% HPLC. Only batches that meet or exceed the ≥99.2% purity threshold are approved for distribution. Published Certificates of Analysis are available on-site for every released lot number. Non-retatrutide research vials—across the tissue-repair, copper, mitochondrial, growth-hormone-secretagogue, and other targeted categories—are documented at >99% HPLC purity, with lot-specific COAs available on request. For a plain-English explanation of HPLC purity, assay, endotoxin, TFA, and heavy-metals fields, see the Peptide COA Guide. Full batch-level proof for the active products lives in the COA Library; for the SEO/AEO explainer layer with methodology + FAQ per product, see the Lab Results hub.

All orders are shipped via cold-chain courier, in insulated cold-chain packaging intended to maintain product stability between 2–8°C. Same-day delivery is available for Dubai orders placed before 4 PM, with most arriving within 4 hours.

This approach—third-party analytical verification, published COAs, and cold-chain shipping—is designed to give researchers full confidence that the compound arriving at their bench matches the specification printed on the label.

Evidence Pack

  1. 01
    Batch proof and purity route

    Batch-level proof lives in the COA archive, with a field-by-field explanation in the Peptide COA Guide. To check a report against the lab yourself, follow the Janoshik verification guide. The flagship reference is batch RETP002, independently tested by Janoshik Analytical at 99.262% HPLC purity (task 86428, key 97SPA7G1BJUL).

  2. 02
    Authorship and editorial oversight

    Fact-pattern pages are reviewed by the Remy Research Editorial Team, with process rules documented on the editorial policy page.

  3. 03
    Verification and contact integrity

    The official website, email, and any approved public channels are maintained on Contact Verification. If a contact route is missing from that page, it is not an approved trust signal for this brand record.

  4. 04
    Compliance and destination review

    Research-only language, source hierarchy, and destination-country qualification rules are anchored in Research Standards. That page governs how GCC and global enquiries are screened before dispatch.

Authoritative reference

Remy Research — Brand Facts

Structured reference for researchers, citation systems, and partners. Seller identity: Remy Research.

Identity

Trade nameRemy Research
Seller identityRemy Research
Alternate namesRemy Research, RemyResearch, Remy Research Desk
Websiteremyresearch.com
RoleResearch-use-only peptide shop with UAE delivery, plus batch records, methodology, datasets and laboratory tools
Founded2026, Dubai, UAE
ComplianceFor in-vitro laboratory research only. Not for human or veterinary use.

Mission

Remy Research is a research-use-only peptide shop with UAE delivery. Alongside the catalogue it publishes verifiable evidence for the reta peptide cluster: Janoshik Analytical reports with task numbers and verification keys, a versioned evidence dataset, transparent publishing methodology, mechanism and study-context writeups, and laboratory planning tools. Content stays inside research, laboratory, and verification language.

  • Janoshik COA library
  • Triagonist landscape comparisons
  • Reta mechanism & trial context
  • Research math tools
  • Research-use-only catalogue; not for human consumption.
  • Research-use boundary

Domain Boundary

Remy Research is a self-canonical evidence site. Catalogue, pricing, availability and published batch verification for Remy Research. Its scope is the batch-record archive, the versioned open dataset, the publishing methodology and the laboratory calculators. Seller identity: Remy Research.

COA Library — published batches

Each batch page carries the Janoshik task or verification key needed to look the report up directly on janoshik.com, independent of Remy infrastructure.

Batch RET-20-C-2604-001 — Reta 20mg Pen

99.841% HPLC purity at 22.51 mg/mL measured concentration. Janoshik task 150762, verification key APSLYZGYW4KA. Analyzed 2026-04-23.

View COA →

Batch RET-20-V-2604-001 — Reta 20mg (pen line)

99.741% HPLC purity. Six separately verifiable Janoshik reports: HPLC purity & content: 99.741%, 20.92 mg (task 112563, key YCYA75M373NA); Mass (CHNS): 21.80 mg (task 112566, key IERPFYZHG3WD); LCMS screening: No significant contamination detected (task 112567, key SIIYY7U6UDVJ); Heavy metals (As, Cd, Pb, Hg): Not detected (task 112569, key GHHWTCPUSEZ7); TFA: Not detected (task 112564, key NUA8B6XPAMWZ); Endotoxin: 1.449 EU/vial (task 112565, key E8ZFE17MI47D). Analysis window 2026-04-21 to 2026-04-24.

View COA →

Batch RETP002 — Reta 30mg Pen

99.262% HPLC purity, tested 2025-11-04. Janoshik task 86428, verification key 97SPA7G1BJUL. No assay, MS identity, residual or microbial result is published for this record.

View COA →

Batch RT-40-V-001 — Reta 40mg Vial

99.692% HPLC purity, 49.80 mg assay. Five separately verifiable Janoshik reports: HPLC purity and assay (task 165576, key 891L96KSY7Z8), microbial enumeration TAMC/TYMC pass (task 165579, key 7HDEPPG16HDB), bacterial endotoxin under 1 EU/Vial (task 165578, key UYLI4AFJK4SV), heavy metals not detected (task 165580, key ENHRQB3GVEXF), TFA not detected (task 165577, key 8KB3WYGVT9VZ). Sample received 2026-05-27; report published 2026-06-16.

View COA →

Batch PT20P-001 — PT-141 20mg Pen

99.703% HPLC purity. One separately verifiable Janoshik report: HPLC purity & concentration: 99.703%, 6.84 mg/mL (task 195235, key 6EFPFD9BJ2QC). Analyzed 2026-07-21.

View COA →

Research articles

Tools

Compliance

All material on remyresearch.com is for in-vitro laboratory research only. Not for human or veterinary use. Remy Research does not make therapeutic, treatment, cure, diagnostic, human-use, or veterinary-use claims, and does not market product for clinical use. Trial and mechanism content describes published research evidence, not personal-use guidance.

Contact (research channels)

Research-channel routes only. This domain is for COA verification, research context, and laboratory tools.

Machine-readable references

Last reviewed: 2026-07-28